Nan Shan Life Insurance Co. Ltd. Decreases Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Nan Shan Life Insurance Co. Ltd. lessened its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 26.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 943,596 shares of the biopharmaceutical company's stock after selling 338,032 shares during the period. Bristol-Myers Squibb makes up approximately 1.3% of Nan Shan Life Insurance Co. Ltd.'s portfolio, making the stock its 21st largest position. Nan Shan Life Insurance Co. Ltd.'s holdings in Bristol-Myers Squibb were worth $53,370,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nearwater Capital Markets Ltd purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $15,837,000. NorthRock Partners LLC lifted its position in shares of Bristol-Myers Squibb by 192.8% during the 4th quarter. NorthRock Partners LLC now owns 26,839 shares of the biopharmaceutical company's stock worth $1,518,000 after purchasing an additional 17,672 shares during the last quarter. Nuveen Asset Management LLC lifted its position in shares of Bristol-Myers Squibb by 16.1% during the 4th quarter. Nuveen Asset Management LLC now owns 10,420,945 shares of the biopharmaceutical company's stock worth $589,409,000 after purchasing an additional 1,444,822 shares during the last quarter. Morse Asset Management Inc lifted its position in shares of Bristol-Myers Squibb by 562.9% during the 4th quarter. Morse Asset Management Inc now owns 66,292 shares of the biopharmaceutical company's stock worth $3,749,000 after purchasing an additional 56,292 shares during the last quarter. Finally, Leigh Baldwin & CO. LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $30,207,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on BMY. Citigroup lifted their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. Wells Fargo & Company lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. UBS Group cut their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $58.00.

Insider Activity

In related news, EVP Samit Hirawat acquired 4,250 shares of the firm's stock in a transaction that occurred on Friday, April 25th. The shares were purchased at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Performance

NYSE BMY traded up $0.96 during trading on Friday, reaching $46.77. The company's stock had a trading volume of 12,103,063 shares, compared to its average volume of 13,242,297. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm has a market cap of $95.18 billion, a price-to-earnings ratio of -10.58, a P/E/G ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The business's fifty day moving average price is $53.05 and its 200-day moving average price is $55.97.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's quarterly revenue was down 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($4.40) earnings per share. As a group, analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.30%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb's payout ratio is 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.